David M. Epstein has sold BDTX and made no open-market buys since Oct 2020

David M. Epstein, Ph.D., is a biopharmaceutical executive and scientist best known as the co‑founder and former President and Chief Executive Officer of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical‑stage precision oncology company targeting families of oncogenic mutations in genetically defined cancers.( As CEO, he led Black Diamond through its January 2020 IPO and the clinical proof‑of‑concept of its EGFR MasterKey inhibitor in 2023, and following a 2023 CEO transition he continued to serve on the company’s Board of Directors.( In this capacity he has been a corporate insider in connection with his equity holdings and Form 4 filings at Black Diamond Therapeutics.(

Epstein has built a broad career leading R&D organizations across academia, start‑ups, mid‑size, and global pharmaceutical companies, including prior roles as Vice Dean, Innovation & Entrepreneurship and Associate Professor of Cancer & Stem Cell Biology at Duke‑NUS Medical School in Singapore, Chief Scientific Officer at OSI Pharmaceuticals (later acquired by Astellas Pharma), and founder/director of Archemix Corporation, where he helped advance multiple clinical candidates in oncology, cardiovascular disease, retinal degeneration, and age‑related macular degeneration.( He is also a co‑founder and currently President and CEO of PairX Bio, a Singapore‑based biotechnology company developing next‑generation cancer‑selective biologics, and serves on the Board of Gyre Therapeutics and other biotech enterprises.( Epstein earned his Ph.D. in Biochemistry from Brandeis University, completed a joint post‑doctoral fellowship in protein structure, function, and NMR dynamics between Penn State and The Scripps Research Institute, and holds a B.Sc. in Chemistry from Lewis & Clark College.(

Written by Perplexity from public sources.